ClinicalTrials.gg
RecruitingNCT07016802Updated Apr 14, 2026

A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)

A Phase 1 interventional study of GenSci134 and Placebo in Safety, Tolerability and Adult Growth Hormone Deficiency, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Dwarfism, Pituitary by Changchun GeneScience Pharmaceutical Co., Ltd. — 3 open to participants now, 3 under way, 2 of them phase 3. Dwarfism, Pituitary · Changchun GeneScience Pharmaceutical Co., Ltd..

Planned enrollment
12th of 13
64 · median 180
Started
2025
with 1 other
Phase 1
2 of 13
1 open now
Registered
12th of 13
by date

Among the 13 studies in Dwarfism, Pituitary by Changchun GeneScience Pharmaceutical Co., Ltd., this one is the 12th largest by planned enrollment, is one of 2 that started in 2025, is one of 2 in phase 1, and was the 12th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 13 studies in Dwarfism, Pituitary by Changchun GeneScience Pharmaceutical Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Dwarfism, Pituitary by Changchun GeneScience Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

To check how safe and well-tolerated a single subcutaneous injection of GenSc134 is in healthy male volunteers, a multiple-doses subcutaneous injection of GenSc134 is in healthy volunteers,a single subcutaneous injection of GenSc134 is in AGHD patients.

Read the detailed description

This study consists of two parts: the first part is the study in healthy volunteers, and the second part is the study in AGHD patients.

The first part consists of two phases. Phase Ia is a single-ascending dose study in healthy male volunteers, and Phase Ib is a multiple-ascending dose study healthy male or female volunteers.

The second part is Phase Ic,which is a a single-ascending dose study in AGHD patients.

Phase Ia:GenSci134 was tested in 7 predetermined single dose groups with placebo and positive drug controls to explore the dosage, and to assess its safety, tolerability, pharmacokinetic (PK) characteristics, pharmacodynamic (PD) characteristics, immunogenicity, and exploratory endpoints in 64 healthy adult male volunteers.

Phase Ib:GenSci134 was tested in 3 predetermined multiple dose groups with placebo, and to assess its safety, tolerability, pharmacokinetic (PK) characteristics, pharmacodynamic (PD) characteristics, immunogenicity in 36 healthy adult volunteers.

Phase Ic :GenSci134 was tested in 2 predetermined dose groups with positive drug controls to explore the dosage, and to assess its safety, tolerability, pharmacokinetic (PK) characteristics, pharmacodynamic (PD) characteristics, immunogenicity, and exploratory endpoints in 16 AGHD patients.

03

Conditions studied

  • Safety
  • Tolerability
  • Adult Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The first part in Healthy adult volunteers:

  • Healthy adult male subjects(Phase Ia),or Healthy adult subjects(Phase Ib) aged 18-45 years (inclusive of boundary values);
  • (BMI): 19.0-24.0 kg/m² (inclusive of boundary values);
  • Good health status;
  • Able to understand and willing to sign the Form (ICF), and comply with study requirements and restrictions.

The second part in AGHD patients(Phase Ic):

  • Be able to understand and be willing to sign the written ICF (before any study procedure is performed).
  • Be willing and able to comply with scheduled visits, treatment regimens, laboratory tests, and other specified study procedures.
  • Aged from 20 to 70 years old (inclusive), at the time of signing the ICF.
  • Body mass index (BMI): 18.0-32.0 kg/m² ((inclusive of boundary values).
  • Meeting any of the following diagnostic criteria for growth hormone deficiency:
  • Adult-onset: Participants with GHD due to hypothalamo-pituitary disorder or relevant treatments (surgery, radiotherapy) or other reasons (infection, traumatic craniocerebral injury, etc.); the participant has no relapse or residual disease is stable for more than 1 year after surgery for pituitary adenoma, surgery for craniopharyngioma or other pituitary gland operation.
  • Childhood-onset: Participants with childhood idiopathic, acquired, congenital GHD or childhood GHD for other reasons.
  • Confirmed diagnosis of AGHD (meeting at least one of the following criteria):
  • Insulin tolerance test: peak GH cut-off point ≤ 5 μg/L.
  • Glucagon challenge test:
  • a) Participants with BMI \< 25 kg/m² or high clinical suspicion [≥ 3 pituitary hormone deficiencies (PHDs)] with BMI 25-30 kg/m², peak GH ≤ 3 μg/L.
  • b) Participants with BMI > 30 kg/m² or low clinical suspicion (≤ 2 PHDs) with BMI 25-30 kg/m², peak GH ≤ 1 μg/L.
  • ≥ 3 PHDs and IGF-1 SDS \< -2.0 at screening.
  • Participants who have not previously received human growth hormone (hGH) therapy or are in the of previous hGH therapy.

Exclusion criteria

Exclusion Criteria:

The first part in Healthy adult volunteers:

  • Subjects with significant medical history or clinical manifestations determined by the investigator;
  • History of , intolerance, or allergy to any drug, compound, food, or other substances, or known allergy to any of the study drug;
  • History of neurological or psychiatric disorders, or subjects with impaired consciousness or cognitive dysfunction;
  • Subjects with abnormalities, including but not limited to vital signs or laboratory test results that are abnormal and clinically significant;
  • Subjects with immunodeficiency or diseases at screening;
  • Subjects who have undergone major surgery within 12 months prior to screening;
  • Subjects with a history of neoplastic diseases;
  • Subjects who have participated in any other clinical trial of drugs or medical devices and have used the medicinal product within 28 days or 5 half-lives (whichever is longer) before dosing.

The second part in AGHD patients(Phase Ic):

  • Known or suspected hypersensitivity to the investigational medical product and/or any of its excipients.
  • Female participants who are pregnant, breast-feeding or intend to become pregnant or are of but not using an effective method.
  • Male participants with fertility potential or their partners who do not use an effective contraceptive method.
  • Clinically significant hepatic disease.
  • Clinically significant chronic renal insufficiency.
  • Cardiac failure.
  • Use of any investigational product within 30 days prior to screening or participated in another trial within 30 days prior to dosing.
  • Use of systemic at non-alternative doses within 90 days prior to dosing.
  • Any disorder or treatment which, in the opinion of the investigator, possibly jeopardizes participant's safety or affects his/her compliance with the protocol.
  • History of diabetes mellitus.
  • History of or ongoing malignancy.
  • Active Cushing's syndrome within 24 months prior to dosing.
  • Acute severe diseases resulting in weight loss within 180 days prior to dosing.
  • Use of weight-reducing drugs known to affect body weight significantly within 12 months prior to dosing.
  • Presence of a mental or language disorder that impairs the ability to understand or cooperate with the study, unwillingness to participate, or any other condition that, in the opinion of the investigator or treating physician, renders the participant unsuitable for the trial.
  • Anticipated change in lifestyle during the trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    GenSci134

    Drug: GenSci134

  • Placebo comparator
    GenSc134 Placebo

    Drug: Placebo

  • Active comparator
    Recombinant Human Growth Hormone Injection (Norditropin®)

    Drug: Recombinant Human Growth Hormone Injection (Norditropin®)

Interventions

  • only one dose of GenSci134 to be given, subcutaneous , 7 dose level groups will be assigned.

  • DrugPlacebo

    only one dose of GenSci134 Placebo to be given, subcutaneous , 7 dose level groups will be assigned.

  • A single dose of 0.2 mg/day, administered once daily (QD) for 28 consecutive days.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events and serious adverse events

    Time frame: From Day 0 to Month 3

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Nov 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 12, 2025
StartActual
Jun 9, 2025
Primary completionEst.
Nov 25, 2026
CompletionEst.
Nov 25, 2026
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07016802
Responsible party
Sponsor
First posted
Jun 12, 2025
Start date
Jun 9, 2025
Primary completion
Nov 25, 2026 (estimated)
Completion
Nov 25, 2026 (estimated)
Last update
Apr 14, 2026

Study contacts

Dongyang LIU, PHD
Contact
liudongyang@vip.sina.com
+86 18610966092
Dongyang LIU, PHD
principal investigator · Peking University Third Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GENSCI134

Start the discussion